Hao Xiong

Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity

Wyndham H. Wilson, Owen A. O’Connor, Myron S. Czuczman et al. · The Lancet Oncology · 2010 · 840 citations · Full text

Hematological Malignancy, Medicine, Malignant Blood Disorder +11

Substantial Susceptibility of Chronic Lymphocytic Leukemia to BCL2 Inhibition: Results of a Phase I Study of Navitoclax in Patients With Relapsed or Refractory Disease

Andrew W. Roberts, John F. Seymour, Jennifer R. Brown et al. · Journal of Clinical Oncology · 2011 · 808 citations · Full text

Phase I Study of Navitoclax (ABT-263), a Novel Bcl-2 Family Inhibitor, in Patients With Small-Cell Lung Cancer and Other Solid Tumors

Leena Gandhi, D. Ross Camidge, Moacyr Oliveira et al. · Journal of Clinical Oncology · 2011 · 579 citations · Full text

Bioinspired Multichannel Nerve Guidance Conduit Based on Shape Memory Nanofibers for Potential Application in Peripheral Nerve Repair

Jing Wang, Hao Xiong, Tonghe Zhu et al. · ACS Nano · 2020 · 183 citations

Tissue Engineering, Engineering, Biomimetic Materials +23

Pharmacokinetics of 5 (and 6)-Carboxy-2′,7′-Dichlorofluorescein and Its Diacetate Promoiety in the Liver

Maciej J. Zamek‐Gliszczynski, Hao Xiong, Nita Patel et al. · Journal of Pharmacology and Experimental Therapeutics · 2003 · 169 citations